$IRTC
iRhythm Technologies, Inc. Stock $irtc

$irtc Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000138865822000020 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$81.80M	$322.8M	$78.81M
YoY Change	3.8%	21.74%	33.34%
Cost Of Revenue	$30.52M	$109.3M	$20.50M
YoY Change	48.88%	55.47%	47.27%
Gross Profit	$51.28M	$213.6M	$58.31M
YoY Change	-12.05%	9.58%	29.04%
Gross Profit Margin	62.69%	66.16%	73.99%
Selling, General & Admin	$71.61M	$274.8M	$56.29M
YoY Change	27.22%	39.35%	4.92%
% of Gross Profit	139.64%	128.69%	96.53%
Research & Development	$11.87M	$38.67M	$11.60M
YoY Change	2.33%	-6.43%	25.13%
% of Gross Profit	23.15%	18.11%	19.89%
Depreciation & Amortization	$3.104M	$9.842M	$1.980M
YoY Change	56.77%	42.64%	66.39%
% of Gross Profit	6.05%	4.61%	3.4%
Operating Expenses	$83.48M	$313.5M	$67.89M
YoY Change	22.97%	31.42%	7.92%
Operating Profit	-$32.20M	-$99.94M	-$9.579M
YoY Change	236.14%	128.84%	-45.95%
Interest Expense	-$248.0K	$1.169M	-$370.0K
YoY Change	-32.97%	-23.04%	-5.13%
% of Operating Profit
Other Income/Expense, Net	$15.00K	$118.0K	$280.0K
YoY Change	-94.64%	-92.58%	-66.27%
Pretax Income	-$32.43M	-$101.0M	-$9.680M
YoY Change	235.04%	131.63%	-43.98%
Income Tax	$59.00K	$367.0K	-$20.00K
% Of Pretax Income
Net Earnings	-$32.49M	-$101.4M	-$9.651M
YoY Change	236.66%	131.26%	-44.21%
Net Earnings / Revenue	-39.72%	-31.4%	-12.25%
Basic Earnings Per Share		-$3.46
Diluted Earnings Per Share	-$1.104M	-$3.46	-$333.4K
COMMON SHARES
Basic Shares Outstanding	29.43M shares	29.33M shares	28.87M shares
Diluted Shares Outstanding		29.33M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$239.1M	$239.1M	$335.2M
YoY Change	-28.66%	-28.66%	138.5%
Cash & Equivalents	$127.6M	$127.6M	$88.63M
Short-Term Investments	$111.6M	$111.6M	$246.6M
Other Short-Term Assets	$9.693M	$9.693M	$7.400M
YoY Change	30.99%	30.99%	72.09%
Inventory	$10.27M	$10.27M	$5.313M
Prepaid Expenses
Receivables	$46.43M	$46.43M	$29.93M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$305.5M	$305.5M	$377.8M
YoY Change	-19.14%	-19.13%	118.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$55.94M	$140.5M	$34.25M
YoY Change	63.35%	18.09%	29.41%
Goodwill	$862.0K		$862.0K
YoY Change	0.0%		0.0%
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$16.05M	$16.05M	$14.09M
YoY Change	13.92%	13.84%	77.47%
Total Long-Term Assets	$157.4M	$157.4M	$133.9M
YoY Change	17.57%	17.58%	0.37%
TOTAL ASSETS
Total Short-Term Assets	$305.5M	$305.5M	$377.8M
Total Long-Term Assets	$157.4M	$157.4M	$133.9M
Total Assets	$463.0M	$463.0M	$511.7M
YoY Change	-9.53%	-9.52%	67.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.51M	$10.51M	$4.365M
YoY Change	140.76%	138.84%	-47.05%
Accrued Expenses	$51.49M	$62.63M	$40.53M
YoY Change	27.03%	28.6%	23.9%
Deferred Revenue	$3.049M		$930.0K
YoY Change	227.85%		-25.66%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.67M	$11.67M	$11.70M
YoY Change	-0.28%	-0.28%	515.79%
Total Short-Term Liabilities	$87.85M	$87.85M	$65.67M
YoY Change	33.79%	33.72%	26.12%
LONG-TERM LIABILITIES
Long-Term Debt	$9.690M	$9.690M	$21.34M
YoY Change	-54.59%	-54.51%	-35.31%
Other Long-Term Liabilities	$697.0K	$85.91M	$1.830M
YoY Change	-61.91%	3.38%
Total Long-Term Liabilities	$10.39M	$95.60M	$23.17M
YoY Change	-55.17%	-8.43%	-29.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$87.85M	$87.85M	$65.67M
Total Long-Term Liabilities	$10.39M	$95.60M	$23.17M
Total Liabilities	$183.5M	$183.5M	$170.1M
YoY Change	7.83%	7.85%	-0.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$406.0M		-$304.7M
YoY Change	33.27%		17.01%
Common Stock	$685.6M		$646.3M
YoY Change	6.09%		63.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$279.5M	$279.5M	$341.6M
YoY Change
Total Liabilities & Shareholders Equity	$463.0M	$463.0M	$511.7M
YoY Change	-9.53%	-9.52%	67.12%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$32.49M	-$101.4M	-$9.651M
YoY Change	236.66%	131.26%	-44.21%
Depreciation, Depletion And Amortization	$3.104M	$9.842M	$1.980M
YoY Change	56.77%	42.64%	66.39%
Cash From Operating Activities	-$13.05M	-$37.75M	$7.820M
YoY Change	-266.82%	174.39%	-260.91%
INVESTING ACTIVITIES
Capital Expenditures	-$4.625M	$28.07M	-$2.360M
YoY Change	95.97%	107.12%	-80.03%
Acquisitions
YoY Change
Other Investing Activities	-$22.51M	$133.3M	-$15.12M
YoY Change	48.86%	-212.19%	2091.3%
Cash From Investing Activities	-$27.13M	$105.3M	-$17.48M
YoY Change	55.22%	-179.51%	39.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$11.67M
YoY Change		500.15%
Cash From Financing Activities	369.0K	-$28.58M	2.960M
YoY Change	-87.53%	-113.33%	-7.5%
NET CHANGE
Cash From Operating Activities	-13.05M	-$37.75M	7.820M
Cash From Investing Activities	-27.13M	$105.3M	-17.48M
Cash From Financing Activities	369.0K	-$28.58M	2.960M
Net Change In Cash	-39.81M	$38.93M	-6.700M
YoY Change	494.16%	-42.88%	-52.68%
FREE CASH FLOW
Cash From Operating Activities	-$13.05M	-$37.75M	$7.820M
Capital Expenditures	-$4.625M	$28.07M	-$2.360M
Free Cash Flow	-$8.420M	-$65.82M	$10.18M
YoY Change	-182.71%	141.01%	46.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001388658
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-37918
CY2021	dei	Entity Registrant Name EntityRegistrantName	iRhythm Technologies, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8149544
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	699 8th Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94103
CY2021	dei	City Area Code CityAreaCode	415
CY2021	dei	Local Phone Number LocalPhoneNumber	632-5700
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1900000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29513264	shares
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Security12b Title Security12bTitle	Common Stock, Par Value $.001 Per Share
CY2021	dei	Trading Symbol TradingSymbol	IRTC
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127562000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88628000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	111569000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	246589000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	46430000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29932000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	10268000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	5313000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9693000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7363000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	305522000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	377825000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55944000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34247000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84587000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84714000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	862000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	862000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16052000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14091000	USD
CY2021Q4	us-gaap	Assets Assets	462967000	USD
CY2020Q4	us-gaap	Assets Assets	511739000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10509000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4365000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51486000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40532000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3049000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	930000	USD
CY2021Q4	us-gaap	Debt Current DebtCurrent	11667000	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	11667000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11142000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8171000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	87853000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65665000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	9690000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	21339000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	697000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1830000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	85212000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	81293000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	183452000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	170127000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29493726	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29493726	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29019350	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29019350	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	685594000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	646258000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-61000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-406045000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-304684000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	279515000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341612000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	462967000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	511739000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	322825000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	265166000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	214552000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	109258000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	70277000	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	52485000	USD
CY2021	us-gaap	Gross Profit GrossProfit	213567000	USD
CY2020	us-gaap	Gross Profit GrossProfit	194889000	USD
CY2019	us-gaap	Gross Profit GrossProfit	162067000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38671000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41329000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37299000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	274839000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	197233000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	179523000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	313510000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	238562000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	216822000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-99943000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-43673000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-54755000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1169000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1519000	USD
CY2019	us-gaap	Interest Expense InterestExpense	1643000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	118000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1591000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1895000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-100994000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43601000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54503000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	367000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101361000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-43830000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-54568000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.46
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.46
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29331010	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29331010	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27754404	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27754404	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25265918	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25265918	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101361000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-43830000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-54568000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-72000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-71000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	98000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-101433000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43901000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54470000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	52137000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9495000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107294000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5288000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26241000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-54568000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	98000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	135409000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20244000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20244000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	206025000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	10009000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34305000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-43830000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-71000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341612000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8943000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	25853000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56246000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101361000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-72000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	279515000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-101361000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-43830000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-54568000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9842000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6900000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3445000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	54527000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	41515000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	26241000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	37000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1641000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-430000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	884000	USD
CY2021	irtc	Provision For Bad Debt And Contractual Allowance ProvisionForBadDebtAndContractualAllowance	37074000	USD
CY2020	irtc	Provision For Bad Debt And Contractual Allowance ProvisionForBadDebtAndContractualAllowance	31431000	USD
CY2019	irtc	Provision For Bad Debt And Contractual Allowance ProvisionForBadDebtAndContractualAllowance	24647000	USD
CY2021	irtc	Operating Lease Right Of Use Assets Amortization OperatingLeaseRightOfUseAssetsAmortization	6752000	USD
CY2020	irtc	Operating Lease Right Of Use Assets Amortization OperatingLeaseRightOfUseAssetsAmortization	6030000	USD
CY2019	irtc	Operating Lease Right Of Use Assets Amortization OperatingLeaseRightOfUseAssetsAmortization	8953000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53572000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37957000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28725000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-321000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	28000	USD
CY2021	irtc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	264000	USD
CY2020	irtc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-4819000	USD
CY2019	irtc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5241000	USD
CY2020Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	175.00
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4960000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1389000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1974000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2329000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3027000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	696000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1831000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	6149000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4732000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6135000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3881000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5604000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7946000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1308000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6002000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2119000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37753000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13759000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21863000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28067000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13551000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20457000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	122184000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	277510000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	165915000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	14525000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1498000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	255515000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	144145000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	95600000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105264000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-132391000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-89274000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	206025000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	107369000	USD
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	8943000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	20244000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	9495000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	25853000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10009000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5288000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11667000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1944000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28577000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	214316000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111576000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38934000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	68166000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	439000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88628000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20462000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20023000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127562000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88628000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20462000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1194000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1502000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1644000	USD
CY2021	irtc	Property And Equipment Included In Accounts Payable And Accrued Liabilities PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	9000	USD
CY2020	irtc	Property And Equipment Included In Accounts Payable And Accrued Liabilities PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	3000	USD
CY2019	irtc	Property And Equipment Included In Accounts Payable And Accrued Liabilities PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	293000	USD
CY2020Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1257142	shares
CY2021	irtc	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2020	irtc	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2019	irtc	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	77000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6625000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	621000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	88860000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	3593000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1129000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2019Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1575342	shares
CY2019Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	73.00
CY2019Q3	irtc	Underwriters Option To Purchase Additional Shares Of Common Stock UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock	205479	shares
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107300000	USD
CY2020Q3	irtc	Underwriters Option To Purchase Additional Shares Of Common Stock UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock	163975	shares
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	206800000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, contractual allowances, allowance for doubtful accounts, the useful lives of property and equipment, the recoverability of long-lived assets including the estimated usage of the printed circuit board assemblies (“PCBAs”), the incremental borrowing rate for operating leases, accounting for income taxes, and various inputs used in estimating stock-based compensation. Certain of these estimates are impacted by uncertainties surrounding COVID-19 such as revenue recognition, contractual allowances for revenue, allowance for doubtful accounts, and stock based compensation. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div>
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9129000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12711000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	9049000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	7296000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9615000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10515000	USD
CY2020	irtc	Accounts Receivable Contractual Adjustments AccountsReceivableContractualAdjustments	15068000	USD
CY2021	irtc	Allowance For Doubtful Accounts Receivable Write Offs Net Of Recoveries And Other Adjustments AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments	8314000	USD
CY2020	irtc	Allowance For Doubtful Accounts Receivable Write Offs Net Of Recoveries And Other Adjustments AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments	7314000	USD
CY2019	irtc	Allowance For Doubtful Accounts Receivable Write Offs Net Of Recoveries And Other Adjustments AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments	7376000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14012000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12711000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	9049000	USD
CY2020Q4	irtc	Accounts Receivable For Contractual Allowance AccountsReceivableForContractualAllowance	21281000	USD
CY2019Q4	irtc	Accounts Receivable For Contractual Allowance AccountsReceivableForContractualAllowance	15433000	USD
CY2018Q4	irtc	Accounts Receivable For Contractual Allowance AccountsReceivableForContractualAllowance	9205000	USD
CY2021	irtc	Accounts Receivable Allowance For Contractual Adjustments AccountsReceivableAllowanceForContractualAdjustments	27459000	USD
CY2020	irtc	Accounts Receivable Allowance For Contractual Adjustments AccountsReceivableAllowanceForContractualAdjustments	20916000	USD
CY2019	irtc	Accounts Receivable Allowance For Contractual Adjustments AccountsReceivableAllowanceForContractualAdjustments	15518000	USD
CY2021	irtc	Accounts Receivable Contractual Adjustments AccountsReceivableContractualAdjustments	17466000	USD
CY2019	irtc	Accounts Receivable Contractual Adjustments AccountsReceivableContractualAdjustments	9290000	USD
CY2021Q4	irtc	Accounts Receivable For Contractual Allowance AccountsReceivableForContractualAllowance	31274000	USD
CY2020Q4	irtc	Accounts Receivable For Contractual Allowance AccountsReceivableForContractualAllowance	21281000	USD
CY2019Q4	irtc	Accounts Receivable For Contractual Allowance AccountsReceivableForContractualAllowance	15433000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable. Cash balances are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, U.S. government securities, corporate notes, commercial paper and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk with respect to accounts receivable are limited due to the large number of customers comprising the Company’s customer base and their dispersion across many geographies. The Company does not require collateral. The Company records an allowance for doubtful accounts based on the assessment of the collectability of customer accounts, considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. Centers for Medicare and Medicaid Services (“CMS”), accounted for approximately 14%, 27% and 27% of the Company’s revenue for the years ended December 31, 2021, 2020 and 2019, respectively. CMS accounted for 8% and 20% of accounts receivable as of December 31, 2021 and 2020, respectively.</span></div>
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	322825000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	265166000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	214552000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	900000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1200000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	221767000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	61000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	221706000	USD
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	110137000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	111569000	USD
CY2021Q4	irtc	Cash Equivalents And Current And Noncurrent Investments CashEquivalentsAndCurrentAndNoncurrentInvestments	221706000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	306401000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	18000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	306412000	USD
CY2021Q4	irtc	Operating Loss Carryforwards Tax Benefit Recognized OperatingLossCarryforwardsTaxBenefitRecognized	0	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	59823000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	246589000	USD
CY2020Q4	irtc	Cash Equivalents And Current And Noncurrent Investments CashEquivalentsAndCurrentAndNoncurrentInvestments	306412000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	221706000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	306412000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	221706000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	306412000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	81588000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	61000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	81588000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	61000	USD
CY2021	irtc	Available For Sale Debt Securities Maturity Period AvailableForSaleDebtSecuritiesMaturityPeriod	P95D
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	13	investment_security
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	investment_security
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	221706000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	306412000	USD
CY2021Q4	irtc	Inventory And Printed Circuit Board Assemblies InventoryAndPrintedCircuitBoardAssemblies	10268000	USD
CY2020Q4	irtc	Inventory And Printed Circuit Board Assemblies InventoryAndPrintedCircuitBoardAssemblies	5313000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	78648000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48097000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22704000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13850000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55944000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34247000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9800000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6900000	USD
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	7431000	USD
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	6007000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	34484000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	19709000	USD
CY2021Q4	irtc	Accrued Employee Stock Purchase Plan Contribution AccruedEmployeeStockPurchasePlanContribution	1002000	USD
CY2020Q4	irtc	Accrued Employee Stock Purchase Plan Contribution AccruedEmployeeStockPurchasePlanContribution	851000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1724000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1709000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	78000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	121000	USD
CY2021Q4	irtc	Claims Payable Current ClaimsPayableCurrent	2988000	USD
CY2020Q4	irtc	Claims Payable Current ClaimsPayableCurrent	4757000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3779000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7378000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51486000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40532000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	13500000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	12200000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12617000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12912000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13304000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13696000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	14100000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	69898000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	136527000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	40173000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	96354000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y7M13D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	7.27
CY2021Q4	irtc	Collaboration Agreement Milestone Payments CollaborationAgreementMilestonePayments	3000000	USD
CY2021Q4	irtc	Collaboration Agreement Additional Milestone Payments Between2022 And Early2023 CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023	1750000	USD
CY2021Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0425
CY2020Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0425
CY2021Q4	us-gaap	Debt Current DebtCurrent	11667000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	9690000	USD
CY2021Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	21357000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	223000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5560000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	181000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	150000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	59000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	68000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	373000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	240000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	68000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-6000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-11000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-7049000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-20762000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-11000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	367000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-21198000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9172000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11446000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	223000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	181000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	182000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30900000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	177000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	409000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	4856000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	544000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-347000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	89000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	614000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	381000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1426000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1128000	USD
CY2021	irtc	Income Tax Reconciliation Effect Of Tax Cuts And Jobs Act Of2017 IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017	-30000	USD
CY2020	irtc	Income Tax Reconciliation Effect Of Tax Cuts And Jobs Act Of2017 IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017	-9000	USD
CY2019	irtc	Income Tax Reconciliation Effect Of Tax Cuts And Jobs Act Of2017 IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	24111000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	30607000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	35400000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17176000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	367000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	114856000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	91034000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9174000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7110000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9812000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8831000	USD
CY2021Q4	irtc	Deferred Tax Assets Valuation Allowances And Other DeferredTaxAssetsValuationAllowancesAndOther	20988000	USD
CY2020Q4	irtc	Deferred Tax Assets Valuation Allowances And Other DeferredTaxAssetsValuationAllowancesAndOther	14996000	USD
CY2021Q4	irtc	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	23868000	USD
CY2020Q4	irtc	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	22624000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	178698000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	144595000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	154734000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	123803000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23964000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	20792000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3212000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	108000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	20696000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	20634000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	23908000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	20742000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	56000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	50000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	123803000	USD
CY2021	irtc	Valuation Allowance Deferred Tax Asset Additions ValuationAllowanceDeferredTaxAssetAdditions	30931000	USD
CY2021	irtc	Valuation Allowance Deferred Tax Asset Deductions ValuationAllowanceDeferredTaxAssetDeductions	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	154734000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	88433000	USD
CY2020	irtc	Valuation Allowance Deferred Tax Asset Additions ValuationAllowanceDeferredTaxAssetAdditions	35370000	USD
CY2020	irtc	Valuation Allowance Deferred Tax Asset Deductions ValuationAllowanceDeferredTaxAssetDeductions	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	123803000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66435000	USD
CY2019	irtc	Valuation Allowance Deferred Tax Asset Additions ValuationAllowanceDeferredTaxAssetAdditions	21998000	USD
CY2019	irtc	Valuation Allowance Deferred Tax Asset Deductions ValuationAllowanceDeferredTaxAssetDeductions	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	88433000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	464300000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	279100000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2302000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1842000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1459000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	772000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	488000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	383000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	236000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	28000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3310000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2302000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1842000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3300000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2300000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1800000	USD
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11164880	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9740557	shares
CY2021	irtc	Stock Issued During Period Shares Restricted Stock Award Grants In Period StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod	1009457	shares
CY2021	irtc	Stock Issued During Period Shares Restricted Stock Award Vested StockIssuedDuringPeriodSharesRestrictedStockAwardVested	285331	shares
CY2021	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	200019	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2094137	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.20
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	97976000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.40
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20010	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	82.77
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	540307	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.59
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	70593	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	54.54
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1503247	shares
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M4D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	62401000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	868614	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	17.31
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	24752	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	66.89
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	609881	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.18
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M26D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	120163000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	90939	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	31.15
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14836	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	68.81
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	504106	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38675000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	483548	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	39.61
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	37756000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	503884	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	40.95
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	38667000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	38.29
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10900000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	109200000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	36900000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2800000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4900000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7800000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-43830000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-54568000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54527000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41515000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26241000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	800000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y4M24D
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-101361000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29331010	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29331010	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27754404	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27754404	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25265918	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25265918	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.46
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2153667	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1724040	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2389277	shares
CY2021Q4	irtc	Operating Lease Rentable Area OperatingLeaseRentableArea	44616	sqft
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, CA
CY2021	dei	Auditor Firm AuditorFirmId	238

Files In Submission

Name	View Source	Status
0001388658-22-000020-index-headers.html	Edgar Link	pending
0001388658-22-000020-index.html	Edgar Link	pending
0001388658-22-000020.txt	Edgar Link	pending
0001388658-22-000020-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
firstamendmenttodevelopmen.htm	Edgar Link	pending
irtc-20211231.htm	Edgar Link	pending
irtc-20211231.xsd	Edgar Link	pending
irtc-20211231xex231.htm	Edgar Link	pending
irtc-20211231xex311.htm	Edgar Link	pending
irtc-20211231xex312.htm	Edgar Link	pending
irtc-20211231xex321.htm	Edgar Link	pending
irtc-20211231_cal.xml	Edgar Link	unprocessable
irtc-20211231_def.xml	Edgar Link	unprocessable
irtc-20211231_g1.jpg	Edgar Link	pending
irtc-20211231_g10.jpg	Edgar Link	pending
irtc-20211231_g11.jpg	Edgar Link	pending
irtc-20211231_g12.jpg	Edgar Link	pending
irtc-20211231_g13.jpg	Edgar Link	pending
irtc-20211231_g14.jpg	Edgar Link	pending
irtc-20211231_g2.jpg	Edgar Link	pending
irtc-20211231_g3.jpg	Edgar Link	pending
irtc-20211231_g4.jpg	Edgar Link	pending
irtc-20211231_g5.jpg	Edgar Link	pending
irtc-20211231_g6.jpg	Edgar Link	pending
irtc-20211231_g7.jpg	Edgar Link	pending
irtc-20211231_g8.jpg	Edgar Link	pending
irtc-20211231_g9.jpg	Edgar Link	pending
irtc-20211231_htm.xml	Edgar Link	completed
irtc-20211231_lab.xml	Edgar Link	unprocessable
irtc-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
secondamendmenttodevelopme.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRTC
iRhythm Technologies, Inc. Stock $irtc

2021 Q4 Form 10-K Financial Statement

#000138865822000020 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRTC iRhythm Technologies, Inc. Stock $irtc

2021 Q4 Form 10-K Financial Statement

#000138865822000020 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRTC
iRhythm Technologies, Inc. Stock $irtc